Medical Research and Educational Center of the Lomonosov Moscow State University.
Robertson Center for Biostatistics.
Kardiologiia. 2024 Sep 30;64(9):16-27. doi: 10.18087/cardio.2024.9.n2732.
Comparative analysis of clinical, anamnestic, and laboratory and instrumental data of patients with chronic heart failure (CHF) and iron deficiency (ID) diagnosed according to the AHA/ESC/RSC criteria, and CHF patients diagnosed with ID based on decreased transferrin saturation (TSAT) ≤19.8% or serum iron (Fe) ≤13 μmol/l.
An additional analysis of the ID-CHF-RF study was performed. The analyzed population included 498 patients (198 women) with CHF. In addition to the ID criteria provided by the protocol (AHA/ESC/RSC criteria: ferritin <100 μg/l or ferritin from 100 to 299 μg/l and TSAT<20%), concentrations of ID biomarkers were assessed, which showed high sensitivity and specificity for the diagnosis of ID compared to the morphological picture of the bone marrow (TSAT<19.8% or Fe ≤13 μmol/l). Subgroups of patients with ID determined only by the AHA/ESC/RSC criteria, only by the TSAT≤19.8% and Fe ≤13 μmol/l criteria, and by both were analyzed.
ID diagnosed by the AHA/ESC/RSC criteria was found in 83.1% of patients. The TSAT ≤19.8% and Fe ≤13 μmol/l criteria revealed ID in 74.5% of patients. In 341 patients (76.8%), ID was diagnosed using both criteria. Patients with ID diagnosed by the TSAT≤19.8% and Fe≤13 μmol/l criteria, compared with patients with ID diagnosed by the AHA/ESC/RKO criteria, had a 50% lower Fe (9.8 μmol/l vs. 19.4 μmol/l) and a higher incidence of anemia (43.3% vs. 23.3%) and diabetes mellitus (DM) (36.7% and 24.7%). Also, these patients had higher values of body mass index (BMI) and NT-proBNP concentration (2317 [1305;9092] vs. 1691 [709;3856] pg/ml), and lower LV EF values (41.5 [29.0;54.5]% vs. 45.0 [34.0;54.0]%), respectively. The most severe course of CHF and the greatest changes in laboratory tests associated with ID and anemia were observed in patients with ID determined by two criteria. Patients in this group were older, with a higher BMI, more frequent presence of atrial fibrillation, and higher NT-proBNP (4182 [1854;9341] pg/ml).
Patients with isolated low ferritin are characterized by less severe clinical and functional impairment compared to patients with low TSAT or Fe. At the same time, patients with ferritin higher than 300 μg/l and low TSAT and/or Fe were characterized by very severe CHF and a low functional status, although this may not be related with ID. Thus, the use of the ferritin-based criteria of ID may lead to overdiagnosis of ID in some patients and, at the same time, miss some of the most "severe" patients who likely require the ID correction. Patients with ID who show a decrease in all three parameters are likely to benefit most from Fe supplementation. It is advisable to perform additional studies on the effect of Fe supplements on the course and prognosis of the disease in this cohort of patients.
比较根据美国心脏协会/欧洲心脏病学会/欧洲心血管影像学协会(AHA/ESC/RSC)标准诊断的慢性心力衰竭(CHF)和铁缺乏(ID)患者与根据转铁蛋白饱和度(TSAT)≤19.8%或血清铁(Fe)≤13 μmol/l 降低诊断为 ID 的 CHF 患者的临床、病史和实验室及仪器数据的分析。
对 ID-CHF-RF 研究进行了额外分析。分析人群包括 498 名(198 名女性)CHF 患者。除了协议提供的 ID 标准(AHA/ESC/RSC 标准:铁蛋白<100 μg/l 或铁蛋白 100-299 μg/l 和 TSAT<20%)外,还评估了 ID 生物标志物的浓度,与骨髓形态学相比,这些生物标志物对 ID 的诊断具有较高的敏感性和特异性(TSAT<19.8%或 Fe≤13 μmol/l)。分析了仅根据 AHA/ESC/RSC 标准、仅根据 TSAT≤19.8%和 Fe≤13 μmol/l 标准以及同时根据这两个标准确定 ID 的患者亚组。
根据 AHA/ESC/RSC 标准诊断的 ID 患者占 83.1%。TSAT≤19.8%和 Fe≤13 μmol/l 标准在 74.5%的患者中发现 ID。在 341 名患者(76.8%)中,同时使用这两个标准诊断 ID。与根据 AHA/ESC/RKO 标准诊断的 ID 患者相比,根据 TSAT≤19.8%和 Fe≤13 μmol/l 标准诊断的 ID 患者 Fe 水平低 50%(9.8 μmol/l 比 19.4 μmol/l),贫血发生率高 50%(43.3%比 23.3%)和糖尿病(DM)(36.7%比 24.7%)。此外,这些患者的体重指数(BMI)和 NT-proBNP 浓度较高(2317 [1305;9092]比 1691 [709;3856] pg/ml),左心室射血分数(LV EF)值较低(41.5 [29.0;54.5]%比 45.0 [34.0;54.0]%)。在根据两个标准确定 ID 的患者中,观察到 CHF 最严重的病程和与 ID 和贫血相关的实验室检查的最大变化。该组患者年龄较大,BMI 较高,心房颤动的发生率较高,NT-proBNP 水平较高(4182 [1854;9341] pg/ml)。
与 TSAT 或 Fe 低的患者相比,单纯低铁蛋白患者的临床和功能损伤程度较轻。同时,铁蛋白高于 300 μg/l 且 TSAT 和/或 Fe 低的患者 CHF 非常严重,功能状态较低,尽管这可能与 ID 无关。因此,使用基于铁蛋白的 ID 标准可能会导致一些患者 ID 过度诊断,同时错过一些可能需要 ID 纠正的“严重”患者。显示所有三个参数下降的 ID 患者可能最受益于 Fe 补充剂。建议对这一患者队列中 Fe 补充剂对疾病病程和预后的影响进行额外研究。